SNTI
Senti Biosciences, Inc. NASDAQ$0.94
Pre-mkt
$0.96
+1.84%
Mkt Cap $24.8M
52w Low $0.77
5.5% of range
52w High $3.88
50d MA $0.94
200d MA $1.38
P/E (TTM)
-0.4x
EV/EBITDA
-4.1x
P/B
41.0x
Debt/Equity
5.2x
ROE
-1099.3%
P/FCF
-5.4x
RSI (14)
—
ATR (14)
—
Beta
2.12
50d MA
$0.94
200d MA
$1.38
Avg Volume
166.2K
About
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target p…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | AMC | -0.43 | -0.38 | +11.6% | 0.79 | -1.3% | -2.3% | +2.8% | +6.2% | +8.4% | +15.4% | — |
| Nov 13, 2025 | AMC | -0.59 | -0.69 | -16.9% | 1.79 | -2.8% | -10.1% | -19.0% | -4.5% | -1.7% | +1.1% | — |
| Aug 7, 2025 | AMC | -0.90 | -0.56 | +37.8% | 1.54 | +1.9% | +2.6% | -1.3% | -3.9% | +0.0% | -0.6% | — |
| May 6, 2025 | AMC | -0.58 | -1.41 | -143.1% | 3.30 | -3.3% | +0.6% | +0.3% | -1.2% | -1.2% | -6.1% | — |
| Mar 20, 2025 | AMC | -3.13 | -0.67 | +78.6% | 3.51 | +5.4% | +4.8% | +6.0% | +0.9% | +1.1% | -5.1% | — |
| Nov 14, 2024 | AMC | — | -6.31 | — | 2.33 | +6.0% | -7.7% | -10.3% | -6.4% | -9.0% | -9.0% | — |
| Aug 13, 2024 | AMC | — | -2.45 | — | 1.97 | +1.0% | +10.2% | +16.2% | +17.3% | +7.1% | +6.1% | — |
| May 9, 2024 | AMC | — | -2.60 | — | 3.70 | +0.8% | -0.3% | -2.2% | +1.6% | +2.2% | +2.7% | — |
| Mar 21, 2024 | AMC | -0.23 | -4.20 | -1726.1% | 4.70 | -4.5% | -6.6% | -13.2% | -12.3% | -17.0% | -19.8% | — |
| Nov 13, 2023 | AMC | -4.80 | -2.50 | +47.9% | 4.34 | -10.1% | -19.4% | -14.3% | -10.4% | -7.1% | -15.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30 | Chardan Capital | Maintains | Buy → Buy | — | $0.79 | $0.78 | -1.3% | -2.3% | +2.8% | +6.2% | +8.4% | +15.4% |
| Dec 9 | Chardan Capital | Maintains | Buy → Buy | — | $2.39 | $2.84 | +18.8% | -35.6% | -37.7% | -40.6% | -45.2% | -49.4% |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | $1.54 | $1.57 | +1.9% | +2.6% | -1.3% | -3.9% | +0.0% | -0.6% |
| Jun 12 | Chardan Capital | Maintains | Buy → Buy | — | $2.81 | $2.96 | +5.3% | +1.8% | -7.5% | +1.8% | -1.1% | -18.9% |
| May 2 | Chardan Capital | Maintains | Buy → Buy | — | $3.25 | $3.29 | +1.2% | +2.2% | +0.9% | +1.5% | +2.2% | +1.8% |
| Dec 4 | Chardan Capital | Maintains | Buy → Buy | — | $7.14 | $7.07 | -1.0% | -7.4% | -13.2% | -23.0% | -8.7% | -21.3% |
| Dec 2 | Chardan Capital | Maintains | Buy → Buy | — | $2.16 | $7.09 | +228.2% | +363.0% | +230.6% | +206.0% | +187.0% | +154.6% |
| Aug 15 | Chardan Capital | Maintains | Buy → Buy | — | $7.86 | $7.66 | -2.5% | -8.3% | -11.6% | -16.8% | -21.0% | -18.3% |
| May 11 | Chardan Capital | Maintains | Buy → Buy | — | $9.75 | $10.10 | +3.6% | +1.5% | -3.6% | -0.5% | -3.6% | +0.7% |
| Mar 24 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $12.50 | $12.80 | +2.4% | +0.8% | -0.8% | -6.4% | -7.2% | -7.2% |
Recent Filings
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Senti Biosciences stockholders face a tax-neutral reorganization, preserving their share positions without immediate tax consequences, which could signal a strategic merger or restructuring that maintains investor equity value.
Apr 1
8-K
Unknown — 8-K Filing
SNTI's SENTI-202 positive clinical data validates its Gene Circuit platform, potentially de-risking the lead program and justifying continued investor confidence in the pipeline's commercial viability.
Mar 27
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
SNTI entered a $2.0 million material agreement with GeneFab, signaling potential revenue growth and strategic partnership expansion that could strengthen market position and investor confidence.
Mar 19
Data updated apr 27, 2026 2:15am
· Source: massive.com